|
|
PRESS RELEASE
AB SCIENCE RECEIVES HEALTH CANADA APPROVAL LETTER TO COMMENCE PHASE I/II TRIAL OF AB8939 IN
THE TREATMENT OF ACUTE MYELOID LEUKEMIA AML
AB8939 IS A NEW GENERATION SYNTHETIC MICROTUBULE DESTABILIZER WITH THE ABILITY TO OVERCOME
MULTIDRUG RESISTANCE AND HAS BROAD APPLICABILITY AS A POTENT ANTICANCER DRUG
Paris, 22 September, 2021, 6pm CET
AB Science SA Euronext FR0010557264 AB... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
LES RESULTATS DE SURVIE A LONG TERME DU MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE
ONT ETE SELECTIONNES POUR UNE ALLOCUTION EN PLENIERE EN TANT QUE « PRESENTATION ORALE DE
PREMIER PLAN » LORS DE LA RÉUNION ANNUELLE DE LA SOCIÉTÉ ESPAGNOLE DE NEUROLOGIE
Paris, 20 septembre 2021, 19h
AB Science SA Euronext FR0010557264 AB annonce aujourdhui quun résumé des... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
RESULTS FROM LONGTERM SURVIVAL ANALYSIS OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS
SELECTED FOR PLENARY SPEECH AS “STAR ORAL COMMUNICATION” AT THE SPANISH SOCIETY OF
NEUROLOGY ANNUAL MEETING
Paris, 20 September 2021, 7pm CET
AB Science SA Euronext FR0010557264 AB today announced that an abstract on the longterm survival
of masitinib in amyotrophic lateral sclerosis ALS... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
AB SCIENCE ANNONCE AVOIR REÇU LAUTORISATION DE REPRISE DES INCLUSIONS DE PATIENTS DANS SON
ÉTUDE DE PHASE 2 DU MASITINIB DANS LA COVID19, CE QUI SIGNIFIE LA REPRISE DU RECRUTEMENT DANS
LES TROIS ÉTUDES EN COURS AVEC LE MASITINIB
Paris, 16 septembre 2021, 19h30
AB Science SA Euronext FR0010557264 AB annonce aujourdhui avoir reçu lautorisation du Ministère de
la... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
AB SCIENCE ANNOUNCES THAT IT HAS RECEIVED AUTHORIZATION TO RESUME PATIENT ENROLLMENT IN
ITS PHASE 2 COVID19 STUDY OF MASITINIB, SIGNIFIYING RESUMPTION OF RECRUITMENT IN ALL THREE
OF ITS ONGOING MASITINIB STUDIES
Paris, 16 September 2021, 7.30pm CET
AB Science SA Euronext FR0010557264 AB announced today that it has received authorization from the
Russian Health Ministry MoH to... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
AB SCIENCE ANNOUNCES THAT IT HAS RECEIVED NEW AUTHORIZATIONS TO RESUME PATIENT
ENROLLMENT IN ITS PHASE 3 STUDIES OF MASITINIB, CONFIRMING A GLOBAL RESUMPTION OF THESE
STUDIES
Paris, September 14 2021, 6pm CET
AB Science SA Euronext FR0010557264 AB announced today that it has received authorization from the
French National Agency for the Safety of Medicines and Health Products... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUE DE PRESSE
AB SCIENCE ANNONCE AVOIR RECU DE NOUVELLES AUTORISATIONS PORTANT SUR LA REPRISE DES
INCLUSIONS DE SES ETUDES DE PHASE 3 DU MASITINIB, CONFIRMANT UNE REPRISE GLOBALE DE CES
ETUDES
Paris, 14 septembre 2021, 18h
AB Science SA Euronext FR0010557264 AB annonce aujourdhui avoir reçu l’autorisation reprise des
inclusions de la part de l’ANSM France dans l’étude de... Lire le communiqué |
|
| |
|
| |
